期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

吉非替尼与标准化疗对EGFR突变的晚期非小细胞肺癌患者疗效和安全性的比较 被引量：4

The Efficacy and Safety Profile of Gefitinib versus Standard Chemotherapy for Non-Small Cell Lung Cancer with Mutated EGFR
下载PDF
导出
摘要 1文献来源 Makoto M, Akira I, Kunihiko K, et al. Gefitinib or chemotherapy for non-small cell lung cancerwith mutated EGFR [J]. N Engl J Med, 2010, 362（25） ： 2380-2388.
作者 王洁 黄玲
机构地区 北京大学肿瘤医院 广东省人民医院肿瘤中心广东省肺癌研究所广东省医学科学院
出处 《循证医学》 CSCD 2011年第1期25-27,30,共4页 The Journal of Evidence-Based Medicine
关键词 肺肿瘤:表皮生长因子受体 酪氨酸激酶抑制剂 敏感突变 标准化疗 疗效 安全性 lung pneoplasms epidermal growth factor receptor tyrosine kinase inhibitor sensitive mutations standard chemotherapy efficacy safety profile
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Atcher N,Chang A,Parikh P,et al.Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer:Results from a randomised,placebo-controlled,multicentre study (Iressa Survival Evaluation in Lung Cancer)[J].Lancet,2005,366 (9496):1527-1537. 被引量：1
  • 2Shepherd FA,Rodrigues Pereira J,Ciuleanu T,et al.Erlotinib in previously treated non-small-cell lung cancer[J].N Engl J Med,2005,353(2):123-132. 被引量：1
  • 3Kim ES,Hirsh V,Mok T,et al.Gefitinib versus Docetaxel in previously treated non-small-cell lung cancer (INTEREST):A randomised phase Ⅲ trial[J].Lancet,2008,372(9652):1809-1818. 被引量：1
  • 4Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or Carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361 (10):947-957. 被引量：1
  • 5Lee JS,Park K,Kim SW,et al.A randomized phase Ⅲ study of Gefitinib versus standard chemotherapy (Gemcitabine plus Cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the Lung[abstract] [J].J Thorac Oncol,2009,4(Suppl 1):PRS4. 被引量：1
  • 6Maemondo M,Inoue A,Kobayashi K,et al.Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J].N Engl J Med,2010,362(25):2380-2388. 被引量：1
  • 7Itsudomi T,Morita S,Yatabe Y,et al.Gefitinib versus Cisplatin plus Docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405):An open label,randomised phase 3 trial[J].Lancet Oncol,2010,11(2):121-128. 被引量：1
  • 8Zhou C,Wu Yi-Long,Lu Shun,et al.Efficacy results from the randomised phase Ⅲ OPTIMAL (CTONG 0802) study comparing first-line Erlotinib versus Carboplatin plus Gemcitabine,in chinese advanced non-small-cell lung cancer patients with EGFR activating mutations[J].ESMO,2010,Abstract LBA13. 被引量：1
  • 9Rosell R,Moran T,Queralt C,et al.Screening for epidermal growth factor receptor mutations in lung cancer[J].N Engl J Med,2009,361 (10):958-967. 被引量：1
  • 10Maheswaran S,Sequist LV,Nagrath S et al.Detection of mutations in EGFR in circulating lung-cancer cells[J].N Engl J Med,2008,359(4):366-377. 被引量：1

同被引文献57

  • 1柴红,陈泽泉,余永利.甲状腺髓样癌靶向治疗新进展[J].上海交通大学学报（医学版）,2011,31(10):1470-1474. 被引量：3
  • 2管忠震,张力,李龙芸,蒋国梁,刘叙仪,储大同,赵洪云,李玮.吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究[J].癌症,2005,24(8):980-984. 被引量：114
  • 3Brambilla E,Travis WD,Colby TV, et al.The new World Health Organization classification of lung tumours[J].Ear Respir J,2001, 18(6): 1059-1068. 被引量：1
  • 4Wang X,Nelson R,Bogardus A,et al.Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival?[J].Cancer,2010,116(6): 1518-1525. 被引量：1
  • 5Lin Weichun,Chiu Chao-hua,Liou Jialing,et al.Ge tinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer[J].Lung Cancer,2011,71(3):193-199. 被引量：1
  • 6Fukuoka M,Yano S,Giaccone G,et al.Multi-Institutional Randomized PhaseⅡTrial of Ge tinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer(the IDEAL1 Trial)[J].J Clin Oncol,2003,21(12):2237-2246. 被引量：1
  • 7Cohen M,Williams G,Sridhara R,et al.FDA drug approval summary:gefitinib(ZD1839)(Iressa)tablets[J].Oncologist,2003,8(4):303-306. 被引量：1
  • 8Cufer T,Vrdoljak E,Gaafar R,et al.PhaseⅡopen-label randomized study(SIGN)of single-agent gefitinib(IRESSA)or docetaxel as econd-line therapy in patients with advanced(stageⅢb or IV)nonsmall-cell lung cancer[J].Anticancer Drugs,2006,17(4):401-409. 被引量：1
  • 9Thatcher N,Chang A,Parikh P,et al.Gefitinib plus best supportive care in previously treated patients with refractory advanced on-smallcell lung cancer:results from a randomized,placebo controlled,multicentre study(Iressa Survival Evaluation in Lung Cancer)[J].Lancet,2005,366:1527-1537. 被引量：1
  • 10Niho S.Results of a randomized PhaseⅢstudy to compare the overall survival of gefitinib(IRESSA)versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimens[J].American Society of Clinical Oncology,2007.43rd:June02(Abs LBA7509). 被引量：1

引证文献4

二级引证文献20

循证医学
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部